uniQure’s (QURE) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of uniQure (NASDAQ:QURE) in a report published on Monday morning, MarketBeat reports. They currently have a $9.00 price objective on the biotechnology company’s stock, down from their previous price objective of $55.00.

QURE has been the subject of several other reports. The Goldman Sachs Group reduced their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Wolfe Research assumed coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Benchmark reissued a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Leerink Partners lowered their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $34.33.

uniQure Price Performance

NASDAQ QURE opened at $9.04 on Monday. The company has a market cap of $565.27 million, a PE ratio of -2.62 and a beta of 0.73. The firm’s 50 day moving average price is $22.54 and its 200-day moving average price is $29.57. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.12 and a current ratio of 10.43. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Sell-side analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 12,378 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the transaction, the chief executive officer owned 639,076 shares in the company, valued at approximately $15,248,353.36. This represents a 1.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 50,598 shares of company stock worth $1,248,588. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the company. Private Trust Co. NA purchased a new position in uniQure in the 3rd quarter worth $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 5.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 533 shares during the period. Arizona State Retirement System raised its stake in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 627 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
• Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
• Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
• Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
• Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
• Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.